Genentech, A Member of the Roche Group

Genentech, A Member of the Roche Group
Share
Considered the founder of the biotechnology industry, Genentech has been delivering on the promise of biotechnology for more than 35 years, using human genetic information to discover, develop, manufacture, and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, Genentech is among the world's leading biotech companies, with multiple products on the market and a promising development pipeline.

Accelerated approval of Perjeta for neoadjuvant use also converted to full approval
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for...

On December 20, 2017, the FDA approved Perjeta® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer at high risk of recurrence.
News in brief
The approval is based on results of the Phase III APHINITY study, which showed...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan® (rituximab) compared to bendamustine plus Rituxan (BR) for the treatment of people with relapsed or refractory chronic lymphocytic leukemia (CLL). The results...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the randomized Phase II GO29365 study that compared polatuzumab vedotin in combination with bendamustine plus Rituxan® (rituximab) (BR) against BR alone in people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not...

Newly approved HEMLIBRA demonstrated superior efficacy compared to prior treatment with bypassing agents as prophylaxis or on-demand Nearly 95 percent of children who received HEMLIBRA experienced zero treated bleeds South San Francisco, CA -- December 9, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today...

Less frequent administration of HEMLIBRA demonstrated clinically meaningful bleed control South San Francisco, CA -- December 6, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive interim results from the Phase III HAVEN 4 study evaluating HEMLIBRA® (emicizumab-kxwh) prophylaxis dosed once every...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has granted full approval for Avastin® (bevacizumab) for the treatment of adults with glioblastoma that progressed following prior therapy (referred to as recurrent disease). Avastin was previously granted...

HAVEN 3 study met primary endpoint and key secondary endpoints Intra-patient comparison demonstrated superiority of HEMLIBRA prophylaxis compared to prior factor VIII prophylaxis South San Francisco, CA -- November 19, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive results from the Phase III...

Data will be submitted to health authorities globally, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) South San Francisco, CA -- November 19, 2017 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of...

First new medicine in nearly 20 years to treat people with hemophilia A with inhibitors HEMLIBRA substantially reduced bleeds in adults and children Only medicine that can be self-administered once weekly by injection under the skin (subcutaneously) South San Francisco, CA -- November 16, 2017 -- Genentech, a member of the Roche Group (SIX: RO,...